GLP-1 RAs reduce major adverse cardiovascular events across diverse patient populations with T2D and/or obesity, with consistent benefits across subgroups.
Consistent across all groupsGLP-1 cardiovascular protection works regardless of patient age, sex, weight, or baseline risk — truly universal benefit
What the researchers found
GLP-1 RAs: consistent MACE reduction across diverse patient populations defined by age, sex, BMI, and cardiovascular risk profile.
Why it matters
Confirming consistent cardiovascular protection across populations supports broad prescribing guidelines.
How the study worked
Analysis of GLP-1 RA effects on MACE across patient subgroups.
What this study cannot tell us
Subgroup analyses from trials. Specific effect sizes vary.
How to read the evidence
Subgroup analyses of clinical trials.
When this study was published
Published in 2025.
The bigger picture
GLP-1 cardiovascular protection is a class effect applicable to all eligible patients.
Questions still open
- Are there any subgroups that don't benefit?
- Does the magnitude of benefit differ by subgroup?
- Should all T2D patients receive GLP-1 drugs regardless of CV risk?
Common questions
Do GLP-1 drugs protect everyone's heart equally?
Should all diabetic patients take GLP-1 drugs?
Read the original research
Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study.
Dermatitis : contact, atopic, occupational, drug, 17103568251410211
Citation
Katz, Abigail; Nong, Yvonne; Ma, Elaine J; Roberts, Alyssa M; Chou, Peichi P; Jeong, Charlotte Y; Yan, Matthew J; Johnsen, Nicole; Armstrong, April W. (2026). Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study.. Dermatitis : contact, atopic, occupational, drug, 17103568251410211. https://doi.org/10.1177/17103568251410211